Home

AAPS Career Development

oct18-careerdev

AAPS Career Development Programming at PharmSci 360

Master crucial conversations, find a job at the Career Development Center, get a critique of your résumé and LinkedIn profile, join student activities, and more.

Read More

AAPS Publications

oct18-pubs

Encouraging Transparency

AAPS journals adopt data sharing policies. In today's competitive, proprietary scientific community, data reproducibility is critical because researchers cannot afford to perform negative experiments. 

Read More

Pharmaceutical Science Update

Posted By Linda Brown
Found In Microsite: AAPS News Magazine
October 10, 2018 The Trump administration is moving forward on its newly cemented trade pact with Mexico and Canada and is taking data protection for complex, expensive drugs along with it. New biologic drugs, which are expensive to develop and made ...
Posted By Linda Brown
Found In Microsite: AAPS News Magazine
October 10, 2018 Biomedical solutions to the opioid crisis could reach patients more quickly under a new authority for the National Institutes of Health (NIH) that will likely become law soon. The White House issued a statement late Oct. 3 confirming ...
Posted By Linda Brown
Found In Microsite: AAPS News Magazine
October 10, 2018 Better individualized disease prevention and treatment strategies based on genetic screening could come from the data generated in a just-started National Institutes of Health (NIH) million-person study. Francis S. Collins, NIH director, ...
Posted By Linda Brown
Found In Microsite: AAPS News Magazine
October 10, 2018 Drug decisions based on data from real-life experiences have raised concerns about scientists cherry picking from different databases to generate the results they want, a Food and Drug Administration (FDA) deputy director said. “My ...
Posted By Linda Brown
Found In Microsite: AAPS News Magazine
October 3, 2018 Old-school clinical trial designs are getting a face lift from the Food and Drug Administration (FDA) as part of the agency’s push to lower drugmakers’ development costs and spur more efficient research. FDA wants drugmakers and policy ...